A Study to Evaluate the Efficacy and Safety of DA-1229 (Evogliptin) in Patient's Calcific Aortic Valve Disease With Mild to Moderate Aortic Stenosis (EVOID-AS)
Stopped The study is suspended due to sponsor's business decision. There were no safety issues influencing this course of action.
Conditions
- Calcific Aortic Valve Disease
Interventions
- DRUG: Evogliptin
- DRUG: Placebo
Sponsor
REDNVIA Co., Ltd.